Congratulations to our CEO, President and Founder, Dr. Emil Kakkis,  on being honored as BIO’s 2019 Henri A. Termeer Biotechnology Visionary Award recipient for his transformative work in rare diseases. Read more.

February 27, 2020
Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)

February 21, 2020
Ultragenyx to Present at SVB Leerink Global Healthcare Conference

February 13, 2020
Ultragenyx Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update